Posts Tagged ‘IMMU’

Another Immune Company Play – Immunomedics

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Cancer is a class of diseases in which a group of cells display uncontrolled growth.  Some cancers invade or intrude upon adjacent tissues, then destroy that tissue/organ, and then spread (metastasize) to other locations in the body via lymph or blood.  These three malignant properties of cancers differentiate them from benign tumors, which do not invade or metastasize.  All of these diseases suggest that there will be a need for personalized therapy, as even within a specific type of cancer, there is wide heterogeneity in clinicopathological features.  For instance, leukemia, lymphoma, myeloma, etc are all lymphoproliferative disorders (where lymphocytes are produced in excess) affect one or more different biological pathways that play a role in lymphomagenesis (the development of B cells and T cells).  Over the past year, on focal point of our  investment virtual portfolio has been smaller companies researching and developing treatments for cancer (CRIS, ARIA, ARRY, SPPI, IMGN).  The next small company with some very interesting prospects in the pipeline is Immunomedics.

Figure 1.  Cancer Prevalence.

In our recent past, monoclonal antibodies (mAbs) were discussed in the context of a mid-tiered pharma, BIIB and smaller biotech, Immunogen (IMGN).  These companies will not be rehashed, but to re-emphasize that mAb and biologics are one of the hottest areas in in biotech.  Small molecules have are not the favorites for now (especially in cancer), and that is most likely due to early stage trials, lack of efficacy, or more likely – patent protection, as biologics/mAbs are harder to show equivolance….and thus have the potential to generate cash for years to come. 

(IMMU) based in New Jersey, is primarily focused on the development of mAb-based products for the targeted treatment of cancer, autoimmune and other diseases.  The company has a number of advanced mAbs that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents (think Inmunogen, but different 'targets').  The company has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action discussed below.  The company also owns a stake in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology. …
continue reading


Tags: , ,




Wild and Crazy Options Action on AIG

Today’s tickers: AIG, IMMU, XHB & NCS

AIG - Investors displayed what can only be described as options-mania today as more than 411,000 contracts (and rising) were traded on the stock by lunchtime. Shares have exploded upwards by more than 28% to stand at the current price of $48.46. Option implied volatility, or the measure of investor uncertainty, jumped up from 114% at the opening bell to the current reading of 150%. Near-term uber-bulls were observed purchasing more than 7,500 calls as high as the September 70 strike price for an average premium of 1.20 apiece. The call premium at that strike – the highest strike price listed for the stock – has nearly doubled during the trading session. Early-bird rewards were apparent as traders who acted first thing this morning (around 10:30 am EDT) were able to purchase the same calls for just 36 cents each. Another trade of note was a bullish reversal established in the November contract. An investor shed 7,500 puts at the November 27 strike price for a premium of 2.50 apiece in order to partially finance the purchase of 7,500 calls at the higher November 55 strike for 4.10 each. The net cost of purchasing the calls was reduced to 1.60. Thus, this individual will begin to realize profits if AIG continues higher by 17% to breach the breakeven point at $56.60 by expiration in November. – American International Group, Inc. –

IMMU - The biopharmaceutical company’s shares have surged 60% higher to reach a new 52-week high of $6.82. Bullish movement in the stock was fueled by news regarding the firm’s experimental epratuzumab drug. Apparently, the drug showed a clinically “meaningful treatment effect” as compared with the placebo in patients with lupus. Option traders responded by positioning for continued upward momentum in IMMU. Call options were coveted at the near-term September 7.5 strike price more than 5,600 times for an average premium of 43 cents per contract. Investors holding the calls are hoping to see the stock rise 16% higher to surpass the breakeven point at $7.93 by expiration next month. Additional bullish action was observed at the November 5.0 strike price where traders shed 2,900 puts for 46 cents a-pop. Perhaps these individuals doubt that shares will slip beneath $5.00 by November’s expiration day. Thus, they are happy to receive the 46 cents premium in exchange for bearing the risk that shares of the…
continue reading


Tags: , , ,




Bearish Put-Spreader Paws Profits at Merck

Today’s tickers: MRK, IMMU, AET, ODP, FSLR, EEM, MFA & XLI

MRK – The pharmaceutical company declared a quarterly dividend of 38 cents per share for the fourth quarter of 2009 today, amid a 3% decline in shares to arrive at the current price of $29.81. A bearish put spread established in the October contract suggests some investors are wary of further declines for the company. The spread involved the purchase of 7,400 puts at the October 31 strike price for 2.23 apiece against the sale of 7,400 puts at the lower October 29 strike for a premium of 1.28 each. The net cost of the transaction amounts to 95 cents, yielding the investor maximum potential profits of 1.05 if the stock slips to $29.00 by expiration. The current market price of MRK is currently lower than the breakeven point on the trade of $30.05. Thus, the investor responsible for the spread has already earned 24 cents by assuming a bearish stance on the stock. – Merck & Company, Inc.

IMMU – Shares of the biopharmaceutical company engaged in the development of products designed to treat cancer, autoimmune, and other serious diseases, have surged more than 14% to $5.24 during the trading session. Bullish movement in the stock was fueled by the news that IMMU has entered into a partnership and cross-licensing agreement with Alexis Biotech Ltd., of London, England. The firms are combining efforts in order to develop “targeted vaccines against cancers” such as melanoma and chronic lymphocytic leukemia, as well as infectious diseases such as AIDS. Option traders hoping for continued upward movement in the price of the underlying were seen getting long of bullish call options in the September contract. The September 7.5 strike price had approximately 3,500 calls coveted for 38 cents apiece. Investors holding the calls will begin to realize profits in the event that shares climb another 50% to surpass the breakeven point at $7.88 by expiration. – Immunomedics, Inc.

AET – The third-largest health insurer in the United States has enjoyed a rally in shares of more than 13% to $29.08 this afternoon after receiving an upgrade to ‘outperform’ from ‘neutral’ at Cowen and Company. Call options exchanged on the stock today exceeded the number of puts by a factor of more than 3-to-1, reflecting bullish sentiment by investors. The near-term August 30 strike price had more than 8,800 calls purchased for
continue reading


Tags: , , , , , , ,




 
 
 

ValueWalk

Central Asia: Challenges Ahead For China's Belt And Road Project

By EurasiaNet. Originally published at ValueWalk.

China’s bid to expand its economic presence in Eurasia – embodied in its “Belt and Road” initiative – requires a major upgrade of railway capacity, especially in Central Asia. Planning and implementing the upgrade entails significant challenges involving coordination, both domestically among various Chinese state agencies and entities, and internationally between China and Central Asian states.

christels / PixabayChina Central Asia

The railway component of the Belt and Road is ambitious, with an abundance of moving parts. The concept relies on ...



more from ValueWalk

Zero Hedge

Larry Fink Lashes Out At Trump Tax Plan: America's On "A Path To Exploding Deficits"

Courtesy of ZeroHedge. View original post here.

The US economy is on "pause" because of the new administration, according to Blackrock's Larry Fink, and Trump's tax proposals are unlikely to spur enough economic growth (due to demographics), leaving America "on the path to exploding deficits."

Just a week after the CEO of the world's largest asset manager said that “the warning signs are getting darker" and pointed to slowing auto ...



more from Tyler

Phil's Favorites

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

The US economy just grew at its slowest pace in 3 years (Business Insider)

The US economy grew by 0.7% in the first quarter, weaker than expected, according to an advance estimate of gross domestic product from the Department of Commerce released on Friday.

Oil's April Rollercoaster Takes It Back to $50 on Supply Dilemma (Bloomberg)

Futures are down 2.4 percent this month in New York after slipping 6.3 percent in March. What’s worrying investors is expanding U.S. crude production, which threatens...



more from Ilene

Market News

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

The US economy just grew at its slowest pace in 3 years (Business Insider)

The US economy grew by 0.7% in the first quarter, weaker than expected, according to an advance estimate of gross domestic product from the Department of Commerce released on Friday.

Oil's April Rollercoaster Takes It Back to $50 on Supply Dilemma (Bloomberg)

Futures are down 2.4 percent this month in New York after slipping 6.3 percent in March. What’s worrying investors is expanding U.S. crude production, which threatens...



more from Paul

Kimble Charting Solutions

Gold Miners; Largest outflows in history could be bullish, says Joe Friday

Courtesy of Chris Kimble.

Could historical outflows present an opportunity? Yesterday Sentimentrader.com reported that outflows from Gold Miners ETF’s GDX and GDXJ topped $800 million on 4/26, the largest single day outflows in history. 

Below looks at Gold Miners ETF GDX, reflecting where these large outflows took place.

CLICK ON CHART TO ENLARGE

The long-term trend since...



more from Kimble C.S.

Insider Scoop

Exclusive: Ritter Pharmaceuticals CEO Talks Stock Scare, Indication Niche

Courtesy of Benzinga.

Andrew Ritter, co-founder and president of Ritter Pharmaceuticals Inc (NASDAQ: RTTR), has found his niche.

There are currently no FDA-approved treatments or reliable over-the-counter remedies for the 40 million Americans suffering lactose intolerance, and to Ritter’s surprise, no biotech firm except his is focusing in on the space.

“I don’t know [wh...



http://www.insidercow.com/ more from Insider

Chart School

Semiconductors Tick Along

Courtesy of Declan.

It was another quiet day for indices but the Semiconductor index was able to add over 1% on the day. This also helped post gains to the Nasdaq 100, although there was a relative gain for the Semiconductor Index against the latter index.


The Nasdaq 100 registered an accumulation day despite its underperformance against Small Caps. The index remains well placed to make a move to upper channel resistance.

...

more from Chart School

Digital Currencies

Bitcoin Spikes To Record Highs

Courtesy of ZeroHedge. View original post here.

US dollar prices for virtual currencies are soaring. Both Bitcoin ($1343 highs) and Ethereum (as we described previously) are at new record highs as China regulators/exchanges appear to have 'stabilized', fears over the so-called 'hard fork' have abated, and hopes for an ETF have been revived by an SEC review.

Back above the price of gold and at record highs, Bitcoin rallied notably overnight after China's largest bitcoin exchanges introduced a flat 0.2% fee on eac...



more from Bitcoin

OpTrader

Swing trading portfolio - week of April 24th, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Members' Corner

Should I buy that stock?

Courtesy of Phil Stasukaitis (pstas)

I was asked by my local investment club to do a presentation on "how to buy a stock?" As I pondered the question, I began by noting all the elements that I monitor regularly and which come in to play as part of my decision process. As the group is comprised novices to experts, I tried to gear my discussion to cover both basics and more advanced concepts.

Four Part Discussion

  1. Macro Economic Indicators
  2. Market Indexes
  3. Fundamental Analysis
  4. Technical Analysis

1. Macro Economic Indicators

We'll start with reviewing some basic concepts and measurements that have direct effects on the stock market. 

A. Gross Domestic Product (GDP)

...

more from Our Members

Mapping The Market

Bombing - Right or Wrong?

Courtesy of Jean-Luc

I am telling you Angel – makes no sense… BTW:

Republicans Love Bombing, But Only When a Republican Does It

By Kevin Drum, Mother Jones

A few days ago I noted that Republican views of the economy changed dramatically when Donald Trump was elected, but Democratic views stayed pretty stable. Apparently Republicans view the economy through a partisan lens but Democrats don't.

Are there other examples of this? Yes indeed. Jeff Stein points to polling data about air strikes against Syria:

Democr...



more from M.T.M.

Biotech

CAR-T & CRISPR - the Future is Now

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

PSW Members....it has been a while since my last post, but since many have all been on the board following the chat, it is time for a scientific lesson in a few of the companies we are long.  In addition, another revolution is coming in the medical field, and it will be touched upon as well.

CAR-T - stands for Chimeric antigen receptors (CARs) and the T is for T-cell.  

From the picture above, T-cells are one cell type of our immune system that fight off infection as well as they are one player at keeping rogue cells from becoming cancerous. Unfortunately, cancer somehow evades the immune system and so it begins.

CAR-T came along in the late1980s via a brilliant scientist, Zelig Eshhar...



more from Biotech

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>